Media Coverage

Quest Diagnostics Inc. this week named a chief information and digital officer, combining two enterprise technology roles, as digital tools continue to expand beyond providing back-room business support and into strategic data management and analytics. Gabrielle Wolfson, a former Xerox Corp. chief information officer, took on the dual role earlier this month at the medical diagnostic-information provider known for blood work, urinalysis and other laboratory tests, a company spokesperson said.

Quest Diagnostics has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories; BBPL’s anatomic pathology division, long-term care division, and Boyce and Bynum Pathology Professional Services are not part of the transaction. Through a separate professional services agreement, BBPPS will become the exclusive pathology provider for Quest clients in Missouri and a preferred pathology provider in the greater Midwestern region. The professional services agreement will go into effect at the time the acquisition is completed, which is expected in the first quarter of 2019.

Quest Diagnostics named Gabrielle Wolfson, a veteran IT business leader, as the company's new senior vice president and chief information and digital officer.

Quest Diagnostics saw fourth-quarter 2018 revenues of $1.84 billion and net income of $127 million. The company should grow by 2% this year, driven by acquisitions, said CEO Steve Rusckowski.

As fentanyl comes and goes in the news, it still remains a serious drug in America. Fentanyl is highly addictive synthetic opioid 50 to 100 times more potent than morphine and 50 times more potent than many forms of heroin. The pharmaceutical drug is manufactured for pain management; however clandestine laboratories also produce the drug and mix in heroin. Sometimes referred to as Apace, China Girl, Dance Fever, or He-Man, the deadly cocktail has infiltrated our streets, neighborhoods, and workplaces.

Quest Diagnostics announced this week that is has completed its previously announced acquisition of the clinical lab services assets of Boyce and Bynum Pathology Laboratories (BBPL). Through a separate professional services agreement, Boyce and Bynum Pathology Professional Services is now the exclusive pathology provider for Quest clients in Missouri, and a preferred pathology provider in the greater Midwest.

Have you heard of cannabidiol (CBD oil)? It's growing in popularity as a natural way to treat epileptic seizures. And more broadly, anxiety and insomnia. The issue is how close CBD is, scientifically, to marijuana.[CR-LF][CR-LF]Marijuana is rich in the compound THC, which gets you high. And while CBD is not pot it does have a tiny bit of THC in it. That has some people wondering if CBD oil can cause someone to fail a drug test. For answers, I'm looking at what federal law says about CBD and I'm reaching out to one of the largest lab-testing companies in America: Quest Diagnostics. Dr. Barry Sample is Quest's director of science and technology. And yes, that's really his name.

Quest Diagnostics today reported a 1 percent year-over-year drop in revenues for the fourth quarter, missing the consensus analyst expectation. Revenue for the three months ended Dec. 31, 2018 was $1.84 billion, down from $1.87 billion in the same quarter last year. The consensus Wall Street estimate was $1.88 billion.

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2018. "In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the marketplace. Quest is well positioned once again in 2019 to deliver on our commitment to grow revenues and earnings, as our in-network status now extends to approximately 90% of commercially insured lives in the U.S.," said Steve Rusckowski, Chairman, CEO and President. "Our guidance for 2019 reflects significant reimbursement pressure offset by strong volume growth and continued execution of our Invigorate program. I am pleased to report our volumes for the year are off to a good start."

Ms. Wolfson is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. These include the company’s Quanum™ suite of healthcare IT solutions and data analytics, myQuest patient mobile app and portal, and digital engagement for the company’s 2,200 patient service centers.

Quest Diagnostics: Q4 Non-GAAP EPS of $1.36 misses by $0.01; GAAP EPS of $0.92 misses by $0.27.

Quest Diagnostics, the world's leading provider of diagnostic information services, and Houston Healthcare are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services for Houston Medical Center and Perry Hospital.

Secaucus-based Quest Diagnostics announced Monday it has completed its previously announced acquisition of the clinical laboratory services business of Boyce & Bynum Pathology Laboratories. BBPL, based in Columbia, Missouri, is a provider of diagnostic and clinical laboratory services in the Midwest. Through a separate agreement, BBPL has been named the exclusive pathology provider for Quest Diagnostic clients in Missouri.

IBM Watson Health today announced an expansion to its partnership with the Broad Institute, providing artificial intelligence to help clinicians mine genomic data to predict patient risk for cardiovascular disease. IBM Watson and the Broad already are a little more than two years into a five-year, $50 million research initiative that seeks to discover the basis for drug resistance in cancers. The Broad is a partner in IBM Watson Genomics from Quest Diagnostics, a service that is available to oncologists nationwide that focuses on oncology diagnostics and providing options for evidence-based methods of treating cancer.

The stigma around marijuana use, both medical and recreational, is slowly dwindling as states throughout the country work towards marijuana legalization. 33 states have officially declared medical marijuana use legal and 10 states have legalized recreational use of the drug. However, a question lingers nationwide regarding views of marijuana in the workplace. All companies hold the right to drug test their employees; however, some industries feel that it’s necessary to test for marijuana regularly while others don’t. On the flip side, there is a large number of companies that don’t drug test as heavily — and that number is growing. With drug tests costing companies around $30 to $50 per employee, many see it as a wasted expense. Quest Diagnostics said that failed drug tests reached an all-time high in 2017 and this is likely to increase as legalization becomes more widespread. Drug testing restricts the job pool, meaning companies aren’t able to find the best candidates for open positions.

The most recent short interest data has been released for the 01/31/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded.

Quest Diagnostics, the world's leading provider of diagnostic information services, announced that it has completed its previously announced acquisition of the clinical laboratory services business of Boyce & Bynum Pathology Laboratories (BBPL), a leading provider of diagnostic and clinical laboratory services in the Midwest.

A diagnostic test used by Mayo Clinic to detect a rare neurological disease involves standard techniques and is not subject to patent law, a federal appeals court ruled Wednesday. The appellate court's decision to uphold a district court ruling in the patent dispute effectively denied claims by Quest Diagnostics' Athena Diagnostics division that it was owed royalties for the testing. The US Court of Appeals for the Federal Circuit sided with Mayo in a 2-1 decision.

Back in 2017, Microsoft first announced the new AI-powered research project under Healthcare NExT initiative that enables healthcare providers to easily create intelligent and compliant healthcare virtual assistants and chatbots. Last year, Microsoft announced the preview of Healthcare Bot service on Azure Marketplace that enabled healthcare organizations to build and deploy, AI-powered virtual health assistants and chatbots. Microsoft today announced the general availability of the service. Virtual health assistants built using this service can be used for enhancing processes, self-service support, and cost reduction efforts. Quest Diagnostics in Cary, NC recently built a bot using the Microsoft Healthcare Bot service. This bot helps Quest Diagnostics' patients in finding testing locations, schedule appointments and get answers to non-medical questions such as whether to fast before a blood test or when to expect results.

Several large health insurance companies, including Aetna, Anthem, and Healthcare Service Corporation, have announced a collaboration with PNC Bank and IBM to utilize blockchain technology to “improve transparency and interoperability in the health care industry” and “address a range of industry challenges, including promoting efficient claims and payment processing, to enable secure and frictionless healthcare information exchanges, and to maintain current and accurate provider directories.” The Synaptic Health Alliance launched in April 2018 with Humana, MultiPlan, Quest Diagnostics, UnitedHealthcare and Optum.

Prism Capital Partners announced it is planning new developments at ON3, a 116-acre campus spanning the cities of Clifton and Nutley Township. The planned construction projects will add approximately 400,000 square feet of laboratory facilities. Prism also stated it is finalizing plans to build a four-story, 150,000-square-foot speculative laboratory building at ON3. Additionally, Quest Diagnostics, leading provider of diagnostic information services, will break ground imminently for a flagship laboratory on a 12-acre parcel. The 250,000-square-foot, owner-occupied lab will become the largest in Quest’s network of 20-plus major laboratory facilities across the country, and will employ more than 1,100 people.

As the industry moves beyond mere EHR adoption and meaningful use, small practices of 10 physicians or fewer told researchers that they want their EMRs to do more than just meet regulatory requirements, a new KLAS report on small physician practices finds. But first, they want the basics to just work better. That means tailoring usability for them and improving customer service. As part of this research, KLAS interviewed representatives from AdvancedMD, Allscripts, Aprima, athenahealth, Azalea Health, CareCloud, Cerner, CureMD, eMDs, Greenway Health, Kareo, NextGen Healthcare, Quest Diagnostics, and Virence Health (GE Healthcare) to determine how well the vendors were aligned with the small practices’ needs and what is driving dissatisfaction among small groups.

Drug testing can be complicated. Much like a baseball player, you must learn the fundamentals of drug testing to execute a successful, drug-free workplace program. No one hits a home run the first time up to bat. Whether you are a drug testing rookie or a veteran, it’s important to understand the benefits of different specimen types and what test type fits the unique needs of your workforce. In our upcoming webinar series, Back to Basics, we take a closer look at the three most common test types for drug testing offered by Quest Diagnostics: urine, hair, and oral fluid.

Americans have multiple numbers at their fingertips, but some of the numbers that could be most important to their health are not among them. New research released today by Quest Diagnostics, the world’s leading provider of diagnostic insights, shows that a majority of adults don’t know vital health information for them or their family members, but nearly all would like to be able to access their health information online. Results from the “Know Your Numbers“ survey show that more people remember their social media log-ins, current bank balances, Wi-Fi-passwords and even the security code on the back of their credit card than they do important personal health data, including their blood type and cholesterol and blood sugar levels.

Mike Sims owns Charlotte CBD on Central Avenue in Charlotte. Their business is exploding and they’ve only been open 18 weeks. “We thought it would be successful but nothing like we’ve seen,” says Owens while a wave of customers shopped in his store. So what if you use a CBD product and have to take a random drug test? We posed that question to Dr. Barry Sample with Quest Diagnostics, the nation’s leading provider in drug testing, where millions of drug tests are administered every year.

A 2017 survey conducted by the National Safety Council found employee use of prescription drugs on the job had affected a majority of employers. The most significant effect was absenteeism or missed work (reported by 39 percent of respondents) followed by impaired or decreased job performance (reported by 29 percent) and safety concerns, such as injuries or near misses (reported by 15 percent). However, a more recent report from December 2018 is cause for even more concern—the use of non-prescription drugs in the workplace.

A 2017 survey conducted by the National Safety Council found employee use of prescription drugs on the job had affected a majority of employers. The most significant effect was absenteeism or missed work (reported by 39 percent of respondents) followed by impaired or decreased job performance (reported by 29 percent) and safety concerns, such as injuries or near misses (reported by 15 percent). However, a more recent report from December 2018 is cause for even more concern—the use of non-prescription drugs in the workplace. A new report published by Quest Diagnostics notes such drug use among the U.S. workforce is increasing at an alarming rate.

Data detailed on Oncology - Chronic Lymphocytic Leukemia have been presented. According to news reporting originating from Marlborough, Massachusetts, by NewsRx correspondents, research stated, "The prognostic role of cytogenetic analysis is well-established in B-cell chronic lymphocytic leukemia (CLL). Approximately 80% of patients have a cytogenetic aberration." Our news editors obtained a quote from the research from Quest Diagnostics, "Interphase FISH panels have been the gold standard for cytogenetic evaluation, but conventional cytogenetics allows detection of additional abnormalities, including translocations, complex karyotypes and multiple clones.

In 2018, five major healthcare companies - Humana, MultiPlan, Optum, Quest Diagnostics, and UnitedHealthcare - formed the Synaptic Health Alliance (the `Alliance`) to explore how blockchain technology could resolve current healthcare issues.

Delta County residents will want to mark their 2019 calendars for Delta County community-wide health fairs which include early blood draw events in early February or health fairs in mid-March in Paonia, Cedaredge and Delta. Delta County Memorial Hospital Volunteers and Lions clubs in Delta, Cedaredge and Paonia will be partnering in the annual community health fair events again. There will be no price increases on the cost of any of the blood work in 2019. Quest Diagnostics will be providing the health screen results in a booklet format to help health fair participants easily understand the meaning of each of the health screen results.

Marijuana is the substance most often detected in workplace drug screenings, according to a new study. More and more employees are testing positive for drugs in workplace screenings, an increase that is concerning for some employers and safety specialists. According to a study by Quest Diagnostics, positive drugs tests have increased significantly in a two-year period between 2015 and 2017.

The idea of sunshine in a bottle vitamin D supplementation — has been promoted as a possible fix for everything from bone and immune system health to depression, dementia and diabetes, and the premise sells. According to recent CDC statistics, approximately 45% of middle-aged women and 38% of middle-aged men report taking a vitamin D supplement, and hundreds of thousands of Americans get tested for vitamin D deficiency each year. VITAL was supported by the NIH. Manson reports she received grants from the NIH, nonfinancial support from BASF, Pharmavite, Pronova BioPharma and Quest Diagnostics during the conduct of the VITAL study. Ng has received research funding from Pharmavite. Bernal-Mizrachi, Clarke and Michos report no relevant financial disclosures.

IBM is collaborating with a group of major players in the healthcare space to improve the way sensitive data is shared and make health claims and transactions more efficient – all in the form of a “blockchain-based ecosystem.” In such a busy space it’s not surprising IBM is faced with some consortia competition. For example, in April of last year, Humana and United Health Group, two of the largest health insurers, teamed up on a blockchain pilot with data providers Quest Diagnostics, Multiplan and Optum.

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2019 for the fourth consecutive year. The annual survey designated Quest Diagnostics as one of only five companies to attain Most Admired status in the "Health Care: Pharmacy and Other Services" industry category.

Good Leads has experience in generating technology sales leads with providers such as Quest Diagnostics, Samsung Neurologica , Fuji Medical, Statlife and Quality Interactions and regularly attends HIMSS and RSNA conferences in support of their IT healthcare and radiology focused customers.

Quest Diagnostics and Oxford Immunotec announced that Quest has completed its acquisition of the U.S. laboratory services business of Oxford Immunotec; the T-Spot.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest’s portfolio of infectious disease testing services.

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 37th Annual J. P. Morgan Healthcare Conference in San Francisco. Stephen Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, January 8, 2019 at 7:30 p.m. Eastern Time. Mr. Rusckowski and Mr. Guinan also will participate in a Q&A session moderated by the host analyst.

The Centers for Disease Control and Prevention (CDC) reported that more than 70,000 people in the United States died of drug overdoses in 2017. That devastating number broke records as the highest number for any single year in our country’s history and contributed to a decrease in life expectancy. Today drug overdoses rank as the leading cause of death for adults under age 55. DownloadQuest Diagnostics white paper about how the opioid crisis affects the workplace.

UBS initiated coverage of Quest Diagnostics and Laboratory Corporation of America on Thursday with a Neutral and Buy rating, respectively. In a report, analyst Kevin Caliendo put a a 12-month price target in Quest's shares of $90 and wrote that while he believes Quest could take market share from LabCorp and other competing reference labs, his analysis of Quest's long-term strategic partnership with UnitedHealthcare, announced in May, "suggests less switching to Quest than is expected."

A recent press release by Quest Diagnostics released new research showing that majority of adults don't know their vital health information, but would like to be able to access their health information online.

The rate of positive drug tests rose by double digits in five of 16 major U.S. workforce industry sectors from 2015 to 2017, according to a recent analysis by lab services provider Quest Diagnostics.

Patient health literacy and knowledge about their own medical information leaves a lot to be desired, leading to calls for better patient education about patient portal and data access, according to a survey conducted by Kelton Global on behalf of Quest Diagnostics.

The rate of positive drug tests rose by double digits in five of 16 major U.S. workforce industry sectors from 2015 to 2017, according to a recent analysis by lab services provider Quest Diagnostics. An examination of data from more than 10 million urine drug tests conducted over the three-year period showed that transportation and warehousing had the largest increase, at 21.4 percent, followed by other services except public administration (15.4 percent), finance and insurance (13), retail trade (12.8), and wholesale trade (11.8).

With trends in drug misuse shifting, Quest Diagnostics is using data mining to help clinicians stay on top of the problem. Quest annually mines and analyzes data from millions of drug tests performed at its laboratories across the country. Last fall, the company released its annual Health Trends, Drug Misuse in America 2018 report, based on 3.9 million de-identified, aggregated lab tests conducted at the Quest laboratories between 2011 and 2017. The mining exercise, and the resulting annual report, are intended to serve as a guide for the clinicians it serves, and for its own laboratories looking to better prepare to meet drug testing needs.

Beginning Jan. 1, 2019, employees and their families who have enrolled with Penn State health benefits will pay the least amount of coinsurance (10 percent), after their deductible, for lab services by using Quest Diagnostics or LabCorp.

Doctors and patients alike need to look at the numbers associated with their hormone levels. The different lab companies that run the blood tests intended to check your hormone levels, such as LabCorp or Quest Diagnostics, have differing ranges for normal, and those may be lowered every few years.

Quest Diagnostics CEO Steve Rusckowski on where the opportunities for growth are for the laboratory-services company, the growth of the health-care sector and efforts to reduce health-care spending in America.

Before you take a vitamin D supplement, you need to get your vitamin D levels checked. This can be done by your doctor, or you can even have it done very inexpensively through a lab such as LabCorp or Quest Labs.

Tom Romeo, general manager of healthcare IT and Quanum Solutions at Quest Diagnostics, recommended hiring the right staff and utilizing their strengths appropriately.

With more and more states legalizing marijuana, you'll often see headlines about how many workers in America are using cannabis. But when you dig into the numbers, it really isn't worth talking about. It should also be noted that all these statistics come from one drug testing lab called Quest Diagnostics. And while Quest Diagnostics is the largest testing lab in the United States, it's not the only one.